Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The BOSTON trial showed that use of once-weekly selinexor, bortezomib, and dexamethasone (SVd) prolonged progression-free survival compared to twice-weekly bortezomib and dexamethasone (Vd) in patients with relapsed or refractory (R/R) multiple myeloma (MM). In this study, we constructed a Markov model to assess the cost-effectiveness of SVd versus Vd in R/R MM. We calculated the incremental cost-effectiveness ratio (ICER) of each treatment strategy from a US payer perspective, using a lifetime horizon and a willingness-to-pay threshold of $150,000 per quality-adjusted life-year (QALY). Use of SVd was associated with an incremental cost of $170,002 compared to Vd alone ($1,015,120 vs. $845,118, respectively), an incremental effectiveness of 0.35 QALYs (3.43 vs. 3.08 QALYs, respectively), and an ICER of $487,361/QALY. These data suggest that use of once-weekly SVd for R/R M/M is unlikely to be cost-effective compared to twice-weekly Vd.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/10428194.2021.1933477 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: Angioimmunoblastic T-cell lymphoma (AITL) is a rare and aggressive form of peripheral T-cell lymphoma, accounting for 1 - 2% of non-Hodgkin lymphomas. Diagnosis is challenging, and there is no established standard first-line treatment. This case report highlights a rare progression from AITL to therapy-related acute myeloid leukemia (AML-pCT) following cytotoxic chemotherapy.
View Article and Find Full Text PDFReal-World Comparison of Treatment Outcomes for Multiple Myeloma in Elderly Transplant Ineligible Patients Receiving First-Line VRd, Rd and VCd: Results From the Australian and New Zealand Myeloma and Related Diseases Registry.
Clin Lymphoma Myeloma Leuk
August 2025
Middlemore Hospital, Auckland, New Zealand.
Background: Real-world data on treatment outcomes for elderly transplant-ineligible patients with newly diagnosed multiple myeloma are limited. The difference in treatment subsidization in Australia compared with New Zealand enables comparison of bortezomib-cyclophosphamide-dexamethasone (VCd), lenalidomide-bortezomib-dexamethasone (VRd) with Rd maintenance, and continuous Rd.
Methods: Using data from the ANZ Myeloma and Related Diseases Registry, we evaluated 1092 patients over 70 years of age between February 2013 and February 2024.
Impact of Dara-VTD induction therapy on stem cell mobilization outcomes in newly diagnosed multiple myeloma patients undergoing autologous stem cell transplantation: a multicenter study.
Ann Hematol
September 2025
Hematology Unit, Department of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Italy.
Daratumumab combined with bortezomib, thalidomide, and dexamethasone (Dara-VTD) is a highly effective induction therapy for newly diagnosed multiple myeloma (NDMM) patients eligible for autologous stem cell transplantation (ASCT). However, its impact on stem cell mobilization requires a critical evaluation. This study examines the effects of Dara-VTD on stem cell mobilization and collection outcomes.
View Article and Find Full Text PDFCardiac light chain amyloidosis secondary to Waldenström's macroglobulinemia: A case report and review.
Exp Ther Med
October 2025
Department of Hematology, Luohu People's Hospital of Shenzhen, Shenzhen, Guangdong 518005, P.R. China.
Cardiac light chain amyloidosis (AL) secondary to Waldenström's macroglobulinemia (WM) presents a complex challenge in medical practice due to its rarity and diagnostic difficulty. A 67-year-old male presented with symptoms of heart failure and was diagnosed with cardiac AL amyloidosis secondary to WM. The diagnosis of WM was confirmed through a combination of immunoglobulin (Ig) profile with abnormal IgM levels, bone marrow morphology, immunofixation electrophoresis, serum protein electrophoresis and gene mutation analysis.
View Article and Find Full Text PDFImmunoglobulin G4 Smoldering Multiple Myeloma With Immunoglobulin G4-Related Autoimmune Hepatitis: A Rare Case Report.
Immun Inflamm Dis
August 2025
Department of Gastroenterology, The First Affiliated Hospital of Dali University, Dali, Yunnan, China.
Background: Multiple myeloma (MM) is a common malignant tumor of the hematological system caused by the malignant proliferation of plasma cells, characterized by the production of M proteins and CRAB symptoms. Among them, the Immunoglobulin G MM is the most common, while the IgG4-MM is extremely rare. Smoldering multiple myeloma refers to a state where there are no clinical symptoms.
View Article and Find Full Text PDF